Istendo (Acetylcysteine)

Acetylcysteine works by breaking disulfide bonds within mucus glycoproteins, which reduces the viscosity of the secretions. This chemical action makes the mucus less sticky, allowing ciliary movement and coughing to clear it more effectively from the respiratory tract.

The dosage of Istendo is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and renal function. The prescriber will set the appropriate amount and frequency according to clinical guidelines and individual needs.

Safety data for acetylcysteine in pregnancy and lactation are limited. The potential benefits should be weighed against possible risks, and the decision to use Istendo during pregnancy or while breastfeeding should be made by a qualified clinician.

To order Istendo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Istendo’s active ingredient, acetylcysteine, directly cleaves disulfide bonds in mucus, offering a rapid reduction in viscosity. Compared with other mucolytics such as carbocysteine or bromhexine, acetylcysteine often provides a more pronounced effect on thick secretions, though choice of therapy depends on patient tolerance, specific indication and clinician preference.

Istendo should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability. Do not freeze the solution, and ensure the container is tightly sealed when not in use.

Istendo is intended for endotracheopulmonary use. It is typically delivered as an inhalation solution via a nebulizer or similar device, allowing the medication to reach the lower airways directly. Administration technique should follow the device manufacturer’s instructions and the prescribing clinician’s guidance.

The most serious risks include severe allergic reactions such as anaphylaxis, bronchospasm that can worsen breathing, rare but serious skin reactions like Stevens‑Johnson syndrome, and potential liver enzyme elevations. Patients should be monitored for any signs of these reactions and seek immediate medical attention if they occur.

Istendo should be avoided in individuals with known hypersensitivity to acetylcysteine or any excipients in the formulation. Patients with uncontrolled asthma or a history of severe bronchospasm should use it only under close medical supervision. Additionally, those with severe renal impairment may require dose adjustment or alternative therapy.